Orteronel
Wikipedia on Answers.com:
Top
Orteronel
| Orteronel | |
|---|---|
 |
|
|
6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide |
|
|
Other names
TAK-700 |
|
| Identifiers | |
| CAS number | 566939-85-3  |
| PubChem | 9883029 |
| ChemSpider | 8058704 |
| UNII | UE5K2FNS92 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C18H17N3O2 |
| Molar mass | 307.35 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Orteronel (TAK-700) is an experimental drug for the treatment of cancer discovered by Takeda Pharmaceutical Company and under development by Millennium Pharmaceuticals.[1] It is currently in Phase III clinical trials for metastatic, hormone-refractory prostate cancer.[2]
Orteronel is an androgen synthesis inhibitor. It selectively inhibits the enzyme CYP17A1[3] which is involved in disease progression in hormone-refractory prostate cancer.
References
- ^ Millennium and Takeda Announce Advancement of Prostate Cancer Program, Millennium Pharmaceuticals
- ^ TAK-700, ClinicalTrials.gov
- ^ Yamaoka, M; Hara, T; Hitaka, T; Kaku, T; Takeuchi, T; Takahashi, J; Asahi, S; Miki, H et al (2012). "Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys". The Journal of steroid biochemistry and molecular biology 129 (3–5): 115–28. doi:10.1016/j.jsbmb.2012.01.001. PMID 22249003.
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Orteronel.
Read more